Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
Mené au Japon sur 30 patients atteints d'un cancer des voies biliaires récidivant ou non résécable, cet essai non randomisé de phase I évalue l'efficacité, du point de vue du taux de réponse objective, de la survie globale et de la survie sans progression, et la toxicité du nivolumab, dispensé en monothérapie ou en combinaison avec une chimiothérapie à base de cisplatine et de gemcitabine
Biliary tract cancers are an increasingly common cause of cancer-associated deaths worldwide, and advanced biliary tract cancers remain difficult to treat. In 2010, the ABC-02 trial 1and a smaller trial in Japan established the combination of gemcitabine plus cisplatin as standard first-line therapy, for patients with advanced biliary tract cancers. The optimal second-line regimen remains undefined, with modest responses observed for various chemotherapy regimens. Progress in genomic analyses have uncovered novel potential drug targets, including mutations (eg, in IDH1 or IDH2, PIK3CA, BRAF, and FGFR1–3), fusions (eg, FGFR1–3, ERBB2–3, and NTRK), and amplifications (eg, FGFR1–3 and ERBB2–3) with varying responses in genomically selected patient subsets
The Lancet Gastroenterology & Hepatology , commentaire, 2018